<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35278170</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-0646</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>40</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Investigational new drugs</Title>
          <ISOAbbreviation>Invest New Drugs</ISOAbbreviation>
        </Journal>
        <ArticleTitle>An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancer.</ArticleTitle>
        <Pagination>
          <StartPage>614</StartPage>
          <EndPage>621</EndPage>
          <MedlinePgn>614-621</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10637-022-01223-9</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Trifluridine/tipiracil (FTD/TPI) and irinotecan are treatment options for heavily pretreated patients with advanced gastric cancer, but their efficacies are limited. We investigated the combination of FTD/TPI and irinotecan for such patients.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS"> Patients who were refractory to fluoropyrimidine, platinum and taxane were enrolled into four cohorts (Level 1A/1B/2A/2B) and treated with irinotecan (100 [Level 1] or 125 [Level 2] mg/m<sup>2</sup> on days 1 and 15) and FTD/TPI (35 mg/m<sup>2</sup>/dose, twice daily, on days 1-5 and 8-12 [Level A] or on days 1-5 and days 15-19 [Level B]) of a 28-day cycle. The primary endpoints were the maximum tolerated dose, dose-limiting toxicities (DLTs), and recommended phase II dose (RP2D); the secondary endpoint was the disease control rate (DCR).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Eleven patients were enrolled: 2 at Level 1A, 3 at Level 1B, and 6 at Level 2B. DLTs occurred in 2/2 patients at Level 1A and 2/6 patients at Level 2B. Grade 3 or higher treatment-related adverse events were neutropenia (90.9%), leukopenia (54.5%), anemia (45.5%) and febrile neutropenia (18.2%). One patient at Level 2B achieved a partial response, and the DCR was 72.7% (95% CI, 39.0%-94.0%). The median progression-free survival and overall survival periods were 3.0 months (95% CI, 0.92-not reached) and 10.2 months (95% CI, 2.2-not reached), respectively.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The RP2D of FTD/TPI combined with irinotecan was determined to be Level 1B; this level was associated with manageable hematologic toxicities and feasible non-hematologic toxicities. Further evaluation of the efficacy of RP2D treatment is necessary.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mizukami</LastName>
            <ForeName>Takuro</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Minashi</LastName>
            <ForeName>Keiko</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Chiba Cancer Center, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hara</LastName>
            <ForeName>Hiroki</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nishina</LastName>
            <ForeName>Tomohiro</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Amanuma</LastName>
            <ForeName>Yusuke</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Chiba Cancer Center, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takahashi</LastName>
            <ForeName>Naoki</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakasya</LastName>
            <ForeName>Akio</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takahashi</LastName>
            <ForeName>Masaki</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakajima</LastName>
            <ForeName>Takako Eguchi</ForeName>
            <Initials>TE</Initials>
            <Identifier Source="ORCID">0000-0002-4589-2335</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan. tnakajima@kuhp.kyoto-u.ac.jp.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Early Clinical Development, Kyoto University Graduate School of Medicine, Kyoto, Japan. tnakajima@kuhp.kyoto-u.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016430">Clinical Trial</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Invest New Drugs</MedlineTA>
        <NlmUniqueID>8309330</NlmUniqueID>
        <ISSNLinking>0167-6997</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011759">Pyrrolidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7673326042</RegistryNumber>
          <NameOfSubstance UI="D000077146">Irinotecan</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>NGO10K751P</RegistryNumber>
          <NameOfSubstance UI="C000613754">tipiracil</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>QR26YLT7LT</RegistryNumber>
          <NameOfSubstance UI="D013941">Thymine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>RMW9V5RW38</RegistryNumber>
          <NameOfSubstance UI="D014271">Trifluridine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077146" MajorTopicYN="N">Irinotecan</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011759" MajorTopicYN="N">Pyrrolidines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013274" MajorTopicYN="Y">Stomach Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013941" MajorTopicYN="N">Thymine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014271" MajorTopicYN="N">Trifluridine</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CPT-11</Keyword>
        <Keyword MajorTopicYN="N">Gastric cancer</Keyword>
        <Keyword MajorTopicYN="N">Irinotecan</Keyword>
        <Keyword MajorTopicYN="N">TAS-102</Keyword>
        <Keyword MajorTopicYN="N">Trifluridine/tipiracil</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>12</Day>
          <Hour>12</Hour>
          <Minute>7</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35278170</ArticleId>
        <ArticleId IdType="doi">10.1007/s10637-022-01223-9</ArticleId>
        <ArticleId IdType="pii">10.1007/s10637-022-01223-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. Epub 2018/09/13.  https://doi.org/10.3322/caac.21492 . PubMed PMID: 30207593</Citation>
        </Reference>
        <Reference>
          <Citation>Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T et al (2013) Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J clinical oncol: official j Am Soc Clinical Oncol 31(35):4438–44. Epub 2013/11/06.  https://doi.org/10.1200/JCO.2012.48.5805 . PubMed PMID: 24190112</Citation>
        </Reference>
        <Reference>
          <Citation>Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. The lancet oncol 15(11):1224–35. Epub 2014/09/23. https://doi.org/10.1016/S1470-2045(14)70420-6 . PubMed PMID: 25240821</Citation>
        </Reference>
        <Reference>
          <Citation>Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N et al (2017) Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. The lancet Gastroenterol hepatol 2(4):277–87. Epub 2017/04/14.  https://doi.org/10.1016/S2468-1253(16)30219-9 . PubMed PMID: 28404157</Citation>
        </Reference>
        <Reference>
          <Citation>Bando H, Shimodaira H, Fujitani K, Takashima A, Yamaguchi K, Nakayama N et al (2018) A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. Eur J Cancer 91:86–91. Epub 2018/01/22.  https://doi.org/10.1016/j.ejca.2017.11.032 . PubMed PMID: 29353164</Citation>
        </Reference>
        <Reference>
          <Citation>Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A et al (2018) Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. The lancet oncol 19(11):1437–48. Epub 2018/10/26.  https://doi.org/10.1016/S1470-2045(18)30739-3 . PubMed PMID: 30355453</Citation>
        </Reference>
        <Reference>
          <Citation>Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538–12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10111):2461–71. Epub 2017/10/11. https://doi.org/10.1016/S0140-6736(17)31827-5 . PubMed PMID: 28993052</Citation>
        </Reference>
        <Reference>
          <Citation>Nishimura T, Iwasa S, Nagashima K, Okita N, Takashima A, Honma Y et al (2017) Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes. Gastric Cancer 20(4):655–62. Epub 2016/11/20.  https://doi.org/10.1007/s10120-016-0670-9 . PubMed PMID: 27858180</Citation>
        </Reference>
        <Reference>
          <Citation>Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D et al (2020) Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med 382(25):2419–30. Epub 2020/05/30.  https://doi.org/10.1056/NEJMoa2004413 . PubMed PMID: 32469182</Citation>
        </Reference>
        <Reference>
          <Citation>Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet376(9742):687–97. Epub 2010/08/24. https://doi.org/10.1016/S0140-6736(10)61121-X . PubMed PMID: 20728210</Citation>
        </Reference>
        <Reference>
          <Citation>Emura T, Nakagawa F, Fujioka A, Ohshimo H, Yokogawa T, Okabe H et al (2004) An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Int J Mol Med 13(2):249–255 (Epub 2004/01/14 PubMed PMID: 14719131)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14719131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doi T, Ohtsu A, Yoshino T, Boku N, Onozawa Y, Fukutomi A et al (2012) Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer 107(3):429–34. Epub 2012/06/28. https://doi.org/10.1038/bjc.2012.274 . PubMed PMID: 22735906; PubMed Central PMCID: PMCPMC3405214</Citation>
        </Reference>
        <Reference>
          <Citation>Bando H, Doi T, Muro K, Yasui H, Nishina T, Yamaguchi K et al (2016) A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201). Eur J Cancer 62:46–53. Epub 2016/05/23.  https://doi.org/10.1016/j.ejca.2016.04.009 . PubMed PMID: 27208903</Citation>
        </Reference>
        <Reference>
          <Citation>Emura T, Murakami Y, Nakagawa F, Fukushima M, Kitazato K (2004) A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med 13(4):545–549 (Epub 2004/03/11 PubMed PMID: 15010854)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15010854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K et al (2011) Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 47(15):2306–14. Epub 2011/07/12. https://doi.org/10.1016/j.ejca.2011.06.002 . PubMed PMID: 21742485</Citation>
        </Reference>
        <Reference>
          <Citation>Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC et al (2012) Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J clinical oncol: official j Am Soc Clinical Oncol 30(13):1513–8. Epub 2012/03/14.  https://doi.org/10.1200/JCO.2011.39.4585 . PubMed PMID: 22412140</Citation>
        </Reference>
        <Reference>
          <Citation>Makiyama A, Arimizu K, Hirano G, Makiyama C, Matsushita Y, Shirakawa T et al (2018) Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer. Gastric Cancer 21(3):464–72. Epub 2017/08/12. https://doi.org/10.1007/s10120-017-0759-9 . PubMed PMID: 28799048</Citation>
        </Reference>
        <Reference>
          <Citation>Nukatsuka M, Nakagawa F, Saito H, Sakata M, Uchida J, Takechi T (2015) Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts. Anticancer Res 35(3):1437–1445 (Epub 2015/03/10 PubMed PMID: 25750295)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25750295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takashi Nishimura SI, Nagashima K, Okita N, Takashima A, Honma Y, Kato K, Hamaguchi K, Yamada Y, Shimada Y, Boku N (2014) Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes. Gastric cancer : official j Int Gastric Cancer Assoc Japanese Gastric Cancer Assoc. Epub 2016 Nov 17. [Epub ahead of print]</Citation>
        </Reference>
        <Reference>
          <Citation>Temmink OH, Hoebe EK, Fukushima M, Peters GJ (2007) Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine. Eur J Cancer 43(1):175–83. Epub 2006/10/20.  https://doi.org/10.1016/j.ejca.2006.08.022 . PubMed PMID: 17049227</Citation>
        </Reference>
        <Reference>
          <Citation>Doi T, Yoshino T, Fuse N, Boku N, Yamazaki K, Koizumi W et al (2015) Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. Investigational new drugs 33(5):1068–77. Epub 2015/07/15.  https://doi.org/10.1007/s10637-015-0271-1 . PubMed PMID: 26163340; PubMed Central PMCID: PMC4768213</Citation>
        </Reference>
        <Reference>
          <Citation>Tomohiro Nishina TY ES, Yamazaki K, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Sugimoto N, Tsuji Y, Moriwaki T, Esaki T, Hamada C, Tanase T, Ohtsu A (2016) Onset of neutropenia as an indicator of treatment response in the randomized phase II of TAS-102 vs placebo in Japanese patients with metastatic colorectal cancer (Study J003–10040030). J Clin Oncol 34, 2016 (suppl; abstr 3557)</Citation>
        </Reference>
        <Reference>
          <Citation>Atsushi Ohtsu TY AF, Garcia-Carbonero R, Argiles G, Alberto FS, Peeters M, Makris L, Benedetti F, Zaniboni A, Shimada Y, Yamazaki K, Komatsu Y, Howard SH, Lenz H-J, Tran B, Wahba M, Yoshida K, Cutsem EV, Robert JM (2016) Onset of neutropenia as an indicator of treatment response in the phase III RECOURSE trial of TAS-102 vs placebo in patients with metastatic colorectal cancer. J Clin Oncol 34, 2016 (suppl; abstr 3556)</Citation>
        </Reference>
        <Reference>
          <Citation>Satake H, Kato T, Oba K, Kotaka M, Kagawa Y, Yasui H et al (2020) Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study). Oncologist 25(12):e1855-e63. Epub 2020/07/16. https://doi.org/10.1634/theoncologist.2020-0643 . PubMed PMID: 32666647</Citation>
        </Reference>
        <Reference>
          <Citation>Varghese AM, Cardin DB, Hersch J, Benson AB, Hochster HS, Makris L et al (2020) Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors. Clin Cancer Res 26(7):1555–62. Epub 2020/01/12.  https://doi.org/10.1158/1078-0432.CCR-19-2743 . PubMed PMID: 31924737</Citation>
        </Reference>
        <Reference>
          <Citation>Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H et al (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11(9):853–60. Epub 2010/08/17.  https://doi.org/10.1016/S1470-2045(10)70181-9 . PubMed PMID: 20708966</Citation>
        </Reference>
        <Reference>
          <Citation>Kawakami T, Machida N, Yasui H, Kawahira M, Kawai S Kito Y et al (2016) Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer. Cancer Chemother Pharmacol 78(4):809–14. Epub 2016/08/28.  https://doi.org/10.1007/s00280-016-3138-z . PubMed PMID: 27566700</Citation>
        </Reference>
        <Reference>
          <Citation>Bang YJ, Ruiz EY, Van Cutsem E, Lee KW, Wyrwicz L, Schenker M et al (2018) Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol 29(10):2052–60. Epub 2018/07/28. https://doi.org/10.1093/annonc/mdy264 . PubMed PMID: 30052729; PubMed Central PMCID: PMCPMC6225815</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
